Young DGK Ich freue mich auf —> Fantastische translationale Medizin ☺️ das wird super spannend und mehr als aktuell. Die translationale Forschung lebt #science #dgk2024jt #science Hannover Medical School Young DGK Thum Lab Thomas Thum Johann Bauersachs Sebastian Feickert

Arrived at the #DGKJahrestagung !! Already enjoying the first afternoon session from Arbeitsgruppe Kardiovaskuläre Regeneration (AG 31) w/ Christian Bär presenting on #cardiac disease and #regeneration using telomeres as a #therapeutic #target Deutsche Gesellschaft für Kardiologie

Amazing talk from Thomas Thum this morning at #DGKJahrestagung! Showing the importance of #miRNAs & their promising potential in the clinics! Wonderful to see the progress from the lab Hannover Medical School, to Cardior Pharmaceuticals - a Novo Nordisk company, to the recent acquisition from Novo Nordisk . So proud!!

On Wednesday April 17 Thomas Thum, Professor of Hannover Medical School and Cardior Pharmaceuticals - a Novo Nordisk company's CSO/CMO is holding a presentation on the development of noncoding #RNA therapeutics for #CDV at Keystone Symposia Cardiovascular Epigenetics and Gene Regulation. Learn more: keystonesymposia.org/conferences/co…

Tomorrow, Dr. Shambhabi Chatterjee will have a presentation at the Keystone Symposia in Hannover! She will be speaking about the importance of #telomerase for #regeneration of #cardiomyocytes. Stop by her session at 17:00! #KSCardioEpi24 keysym.us/KSCardioEpi24

Tomorrow afternoon, Dr. Alessia Costa and Prof. Christian Bär will give insights into tracking #cardiomyocyte proliferation, & long non-coding #RNA as a #therapy for myocardial infarction, in a workshop at the Keystone Symposia at 14:30. #KSCardioEpi24 keysym.us/KSCardioEpi24

Didn't skip a beat. Established a CRISPRi-based hiPSC tool to model telomere length & show short telomeres w/ poor cardiomyogenic potential & cardiomyocytes w/ short telomeres are functionally impaired & vulnerable to stress. Incredible work Shambhabi Chatterjee !! doi.org/10.1007/s00018…

As of May 2, 2024 Cardior Pharmaceuticals - a Novo Nordisk company has become a fully owned subsidiary of Novo Nordisk. Happy to combine forces with Novo Nordisk to accelerate the clinical development of our lead compound with the aim of bringing life-saving treatment to heart patients! Two teams in Hannover.

A milestone for all of us! Proud for our team and innovations that are now significantly pulled forward to become next generation medicines for #heartfailure patients!

Cardior’s founder and CSO/CMO Prof. Thomas Thum will present the exciting journey starting from research on #microRNAs at the bench to clinical testing in heart failure and the potential of #CDR132L to tackle the root causes of acute and chronic HF: escardio.org/Congresses-Eve…

#HeartFailure2024 Remote haemodynamic monitoring with CardioMEMS effectively reduce the primary endpoint across or within each subgroup. A respecified analysis of the MONITOR-HF. #HF #HFA_ESC Carolyn Lam

We are happy to announce Thomas Thum and Dr. Claudia Ulbrich are among the finalists of Andreas & Thomas Struengmann Award, the first of its kind in the DACH region aimed at recognizing entrepreneurial achievements in the life sciences arena: businesswire.com/news/home/2024…

Wonderful opportunity to present our journey from cell cultures to clinical reality employing #dark #genome information to create #RNA-based next generation medicines!

Impressive work w/ a 1st place poster from one of our astounding students Elisa Mohr! @ #cardioascona presenting #CVDs in 3D : the versatility of #cardiac #organoids as multipurpose tool to recapitulate the human #Heart in vitro. Crucial research for #regenerative #cardiology

Congrats Elisa! Our decision a few years ago to invest in #regenerative human model systems pays off 😎

#Telomerase activation as a new therapy for #cardiac disease! New study by our #IMTTS lab members Prof. Christian Bär and Shambhabi Chatterjee !

Congrats!!!! Vicente! (-: